title: [Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
abstract: OBJECTIVE
  Gemcitabine combined with cisplatin has been taken as the front-line regimen for patients with advanced non-small-cell lung cancer (NSCLC). The routine use of gemcitabine is intravenous injection of a dose of 1,000 mg/m(2) within 30 minutes on days 1 and 8, and the treatment is repeated every 3 weeks. This study was to evaluate the efficacy and safety of 6-hour continuous infusion of low dose of gemcitabine plus cisplatin for patients with advanced NSCLC.
  
  
  METHODS
  Forty-eight patients with measurable stage III B/IV NSCLC and without chemotherapy were enrolled. All of them received 6-hour continuous infusion of gemcitabine 250 mg/m(2) on day 1 and 8 plus cisplatin 75 mg/m(2) on day 2-4 for more than 2 cycles. The cycle was repeated every 3 weeks.
  
  
  RESULTS
  All 48 patients were evaluated for toxicity and 46 for response. The overall response rate was 32.5% (completed and partial response rates were 2.2% and 30.3%, respectively). The median time to progression was 5.1 months, median survival time was 10.2 months; and 1-year survival rate was 36.6%. The main hematologic toxicity consisted of 60.4% neutropenia, 39.5% thrombocytopenia. Grade III-IV neutropenia and thrombocytopenia were 20.8% and 12.5%, respectively.
  
  
  CONCLUSIONS
  Six-hour prolonged infusion of low dose gemcitabine combined with cisplatin is a relatively safe and effective regimen for patients with advanced NSCLC.
authors.affiliation: Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, 330006, P. R. China. jpxiong@medmail.com.cn
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Xiong
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.forename: Lu-Xing
authors.initials: LX
authors.lastname: Zhong
authors.forename: Feng
authors.initials: F
authors.lastname: Qiu
authors.forename: Yu-Ling
authors.initials: YL
authors.lastname: Guo
authors.forename: Hong-Yun
authors.initials: HY
authors.lastname: Lian
authors.forename: Hui
authors.initials: H
authors.lastname: Luo
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D012074:Remission Induction; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine